Literature DB >> 19995354

A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.

Thomas M Braun1, Shufang Wang.   

Abstract

We propose a hierarchical model for the probability of dose-limiting toxicity (DLT) for combinations of doses of two therapeutic agents. We apply this model to an adaptive Bayesian trial algorithm whose goal is to identify combinations with DLT rates close to a prespecified target rate. We describe methods for generating prior distributions for the parameters in our model from a basic set of information elicited from clinical investigators. We survey the performance of our algorithm in a series of simulations of a hypothetical trial that examines combinations of four doses of two agents. We also compare the performance of our approach to two existing methods and assess the sensitivity of our approach to the chosen prior distribution.
© 2009, The International Biometric Society.

Entities:  

Mesh:

Year:  2010        PMID: 19995354      PMCID: PMC2889231          DOI: 10.1111/j.1541-0420.2009.01363.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  18 in total

1.  Continual reassessment methods in phase I trials of the combination of two drugs in oncology.

Authors:  A Kramar; A Lebecq; E Candalh
Journal:  Stat Med       Date:  1999-07-30       Impact factor: 2.373

2.  Dose-finding with two agents in Phase I oncology trials.

Authors:  Peter F Thall; Randall E Millikan; Peter Mueller; Sang-Joon Lee
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

3.  Designs for single- or multiple-agent phase I trials.

Authors:  Mark R Conaway; Stephanie Dunbar; Shyamal D Peddada
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

4.  Two-dimensional dose finding in discrete dose space.

Authors:  Kai Wang; Anastasia Ivanova
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

5.  Sequential continual reassessment method for two-dimensional dose finding.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

6.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

7.  Continual reassessment method for ordered groups.

Authors:  John O'Quigley; Xavier Paoletti
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

8.  Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.

Authors:  Robert J Amato; Margaret Morgan; Anish Rawat
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

9.  Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

Authors:  M Inokuchi; T Yamashita; H Yamada; K Kojima; W Ichikawa; Z Nihei; T Kawano; K Sugihara
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

10.  Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.

Authors:  A Azzabi; A N Hughes; P M Calvert; E R Plummer; R Todd; M J Griffin; M J Lind; A Maraveyas; C Kelly; K Fishwick; A H Calvert; A V Boddy
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

View more
  26 in total

1.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

2.  A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.

Authors:  Suyu Liu; Jing Ning
Journal:  Bayesian Anal       Date:  2013-09-09       Impact factor: 3.728

3.  A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.

Authors:  Liangcai Zhang; Ying Yuan
Journal:  Stat Med       Date:  2016-08-31       Impact factor: 2.373

Review 4.  Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Authors:  Ying Yuan; J Jack Lee; Susan G Hilsenbeck
Journal:  JCO Precis Oncol       Date:  2019-10-24

5.  CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.

Authors:  Mohamed Amine Bayar; Anastasia Ivanova; Gwénaël Le Teuff
Journal:  Comput Methods Programs Biomed       Date:  2019-05-06       Impact factor: 5.428

6.  AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Authors:  Jiaying Lyu; Yuan Ji; Naiqing Zhao; Daniel V T Catenacci
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-13       Impact factor: 1.864

7.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

8.  Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.

Authors:  Márcio Augusto Diniz; Mourad Tighiouart
Journal:  J Biom Biostat       Date:  2017-11-27

9.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Authors:  Thomas M Braun; Nan Jia
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

10.  Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.

Authors:  Peter F Thall; Richard C Herrick; Hoang Q Nguyen; John J Venier; J Clift Norris
Journal:  Clin Trials       Date:  2014-09-01       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.